At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 103 enrolled
Drug / intervention
Xentuzumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
In Brief
A Phase 2 clinical trial evaluating Xentuzumab, Placebo, and 2 other interventions for Breast Neoplasms. Completed, enrolled 103 participants across 54 sites in 11 countries.
Detailed Summary
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesAustralia, Belgium, Canada, France, Germany, Greece, Italy, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionAug 2021
Study CompletionMay 2022
TodayJul 2026
First PostedSep 6, 2018
Enrollment StartNov 28, 2018
Primary CompletionAug 30, 2021
Study CompletionMay 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.8 years ago
Interventions
Xentuzumabdrug
Intravenous infusion
Placebodrug
Intravenous infusion
Everolimusdrug
Tablet
Exemestanedrug
Tablet